NanoVibronix (Nasdaq:NAOV) announced today that it launched a next-generation robotic development initiative in its ENvue Medical division.
Tyler, Texas–based NanoVibronix recently acquired ENvue Medical and named its CEO, Doran Besser, as its new CEO. With the acquisition, the company is now developing the ENvue Drive to automate electromagnetic navigation for enteral and vascular access procedures at the bedside.
Now in development, the system would integrate with the FDA-cleared NanoVibronix electromagnetic guidance technology for enteral access. The company aims to provide automated alignment and positional stability while allowing clinicians to remain in full control.
“ENvue’s Drive platform marks a transformative move for bedside clinical care,” said Besser. “By embedding intelligent robotics into high-frequency clinical workflows, starting with feeding tubes and expanding into vascular areas, we believe that we are addressing a major clinical challenge of doing more with fewer hands without compromising precision or safety while giving clinicians a new level of confidence and consistency in care.
“Importantly, the Drive platform is a scalable foundation for intelligent bedside navigation. Through this initiative, we believe we are building a future-ready solution portfolio that can evolve with clinical demands across multiple care settings and drive growth.”
More about the NanoVibronix and ENvue robotic system
The company believes its system can address the growing need to automate high-volume bedside procedures amid workforce shortages and increasing patient complexity.
“Despite these massive procedural volumes, to our knowledge, no intelligent robotic system currently exists to assist with electromagnetic navigation during enteral or vascular access at the bedside,” said Besser. “ENvue Drive aims to fill this gap.”
NanoVibronix says it wants ENvue Drive to augment clinician performance, not replace it, particularly in critical care settings. The company hopes to automate the bedside alignment of its electromagnetic probe for real-time, stabilized positioning during nasoenteric and PICC procedures.
Additionally, the system could reduce the need for multiple clinicians to perform a procedure. It enables hands-free functionality for increased safety, consistency and reproducibility, too.
The company currently has the platform in the preclinical development phase. The engineering of prototypes is in process, and it has clinical advisor input underway, too.
NanoVibronix intends to initiate formal regulatory planning and submission milestones later this year. It anticipates having a functional prototype by the end of the year.
“In the quarters ahead, we expect to share meaningful updates on our hardware and software development progress, new clinical collaborations and advisory board appointments, as well as our regulatory roadmap,” said Besser. “We are also actively pursuing technical partnerships, AI-powered capabilities and clinical research initiatives to further strengthen the impact and scalability of our platform.”
